May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Tissue Distribution and Relative Bioavailability of Ocularly–Administered Moxaverine–HCl
Author Affiliations & Notes
  • U. Becker
    Biopharmaceutics & Pharm. Technology, Saarland University, Saarbruecken, Germany
  • C. Ehrhardt
    Biopharmaceutics & Pharm. Technology, Saarland University, Saarbruecken, Germany
  • U.F. Schaefer
    Biopharmaceutics & Pharm. Technology, Saarland University, Saarbruecken, Germany
  • H.J. Gukasyan
    School of Pharmacy,
    University of Southern California, Los Angeles, CA
  • K.J. Kim
    Keck School of Medicine,
    University of Southern California, Los Angeles, CA
  • V.H. L. Lee
    School of Pharmacy,
    University of Southern California, Los Angeles, CA
  • C.M. Lehr
    Biopharmaceutics & Pharm. Technology, Saarland University, Saarbruecken, Germany
  • Footnotes
    Commercial Relationships  U. Becker, Ursapharm Arzneimittel GmbH & Co. KG F; C. Ehrhardt, None; U.F. Schaefer, None; H.J. Gukasyan, None; K.J. Kim, None; V.H.L. Lee, None; C.M. Lehr, None.
  • Footnotes
    Support  NIH grants EY12356 (VHLL) and HL38658 (KJK)
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3959. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      U. Becker, C. Ehrhardt, U.F. Schaefer, H.J. Gukasyan, K.J. Kim, V.H. L. Lee, C.M. Lehr; Tissue Distribution and Relative Bioavailability of Ocularly–Administered Moxaverine–HCl . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3959.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To study tissue distribution and relative bioavailability of topically–administered moxaverine–HCl to the rabbit eye. Introduction:In this study, we determined whether moxaverine–HCl (MOX), a drug not used in ophthalmic research before, could be delivered to sites of interest by topical application to the eye. Known characteristics of MOX include a high lipophilicity (log P 4.017). A good solubility in aqueous solvents is achieved by forming the HCl salt. Methods:Dutch–belted male pigmented rabbits were placed in a restrainer and 50 µL of an isotonic drug solution, spiked with 14C–moxaverine–HCl were applied to each eye. For the determination of ocular bioavailability after systemic administration, the same solution was given i.v.. At time points of 30 and 120 min, rabbits were sacrificed. From one eye, samples of aqueous humor and vitreous body were taken. The other eye was excised as a whole and dissected to yield the particular intraocular tissues. Tissues were lysed for 12 h, scintillation cocktail was added to the vials containing individual tissue lysates samples and the radioactivity was determined in a scintillation counter. Results:After topical administration, highest levels of MOX were found in conjunctiva, cornea and iris/ciliary body. Lens contained no measurable drug level. Concentrations within the retina were comparable to those obtained after systemic application. Plasma levels after topical dosing were lower compared to systemic dosing. Drug amounts in the sclera were lower following i.v. application at both 30 and 120 min. Conclusions:This study demonstrated the possibility of a targeted delivery of MOX to the posterior part of the eye by using eye drops. Concentrations in the retina were equal (30 min) or even higher (120 min) after topical administration, compared to i.v. application. Acknowledgements: Ms. Dorothea Groß and Dr. Klaus Eschmann (Ursapharm) are thanked for their support of this work.

Keywords: pump/barrier function • pharmacology • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×